PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer

Emerging evidence has shown that adding poly(ADP-ribose) polymerase (PARP) inhibitors to chemotherapy regimens is superior to the control regimens alone in BRCA1-mutated triple-negative breast cancer (TNBC) patients, but their underlying mechanisms have not been fully elucidated. In this study, usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Wei, Tang, Lin, Xu, Yumei, Xu, Jing, Zhang, Wenwen, Xie, Hui, Wang, Shui, Guan, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296748/
https://www.ncbi.nlm.nih.gov/pubmed/28176879
http://dx.doi.org/10.1038/srep42319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296748/
https://www.ncbi.nlm.nih.gov/pubmed/28176879
http://dx.doi.org/10.1038/srep42319

Ejemplares similares